Supporting M&As in the pharmaceutical/biopharmaceutical industry

Manufacturing Chemist: At PharmaLex, we believe we have a unique understanding of the cultural challenges experienced during M&As. Having merged ourselves in 2017 into PharmaLex, we have insight in how to overcome the challenges of maintaining agility while benefiting from working in a bigger corporate environment, having economies of scale with an increased resource pool.

Posted:

Read

Together Beyond COVID-19

PharmaLex.perts Jürgen Hönig and Lisa Pascoe discuss the challenges COVID-19 has placed on the pharma industry – from R&D to clinical trials and manufacturing to drug safety – and how companies like PharmaLex are working together with the industry to ensure regulatory compliance.

Posted:

Read

Drug Development Decisions

Zeb Younes & Zaklina Buljovcic will give you insightful information about new approaches to Drug Development. This article is taken from the European Biopharmaceutical Review October 2019, pages 58-64. © Samedan Ltd.

Posted:

Read

The FDA is shifting focus to both ends of the product development spectrum

PharmaLex’s Andrew S. Verderame looks at how the FDA are introducing new measures to process and approve more complex novel and generic therapies  – p52-53

Posted:

Read

EPR - Are you giving regulatory intelligence the platform it deserves?

PharmaLex’s Jürgen Hönig and Rob Williams discuss the key elements of developing a successful knowledge-management plan – p12

Posted:

Read

Spot the Difference

Torben Thers Nørgaard looks at Scandinavia and how the countries have very different rules and regulations when it comes to doing business: http://www.samedanltd.com/magazine/12.

Posted:

Read

Is there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?

Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit

Posted:

Read

Regulatory intelligence – from knowledge to added value

Dr. Jürgen Hönig and Rob Williams look into the benefits of having the right information.

Posted:

Read

Brexit Uncertainty - impact on medicines supply

PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU

Posted:

Read

Artificial Intelligence in drug development: What are current use cases? - Part 2: Pharmacovigilance

PharmaLex CEO, Tilo Netzer looks at the opportunities for AI in drug development, examining the use cases in relation to pharmacovigilance

Posted:

Read

Artificial Intelligence in drug development: What are current use cases? - Part 1: Regulatory Affairs

PharmaLex CEO, Tilo Netzer looks at the opportunities for AI in drug development, examining the use cases in relation to regulatory affairs

Posted:

Read

The 5 things you want to know about Artificial Intelligence

PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence

Posted:

Read

The Pink Sheet - Big Data: Moving From Artificial Trials To A Smarter Regulatory Process

PharmaLex’s Bruno Boulanger discusses the impact big data will have on how the pharmaceutical industry gathers and delivers data in the future. *subscription required*

Posted:

Read